Ellen Smekens

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Due to its distinct molecular profile and lack of receptor-targeted treatment options, radiotherapy (RT) remains a key component of TNBC management. However, emerging evidence suggests that TNBC may be less responsive to radiation than other breast cancer subtypes. Despite this, current RT protocols remain uniform across all types of breast cancer, with no adjustments made for TNBC’s potential radioresistance.

This research aims to optimize radiotherapy for TNBC patients by investigating radiobiological responses to clinically relevant fractionation schemes. Using preclinical TNBC models, we examine radiation-induced damage, associated repair dynamics, and cellular responses following irradiation. Comparative evaluation of different regimens enables identification of resistance patterns and potential strategies to overcome them. Ultimately, this work aims to inform the development of tailored hypofractionation protocols, ensuring radiotherapy remains a viable and effective option for patients with this hard-to-treat breast cancer subtype.
 

• Lab address: Radiobiology Lab, Campus UZ Ghent, Building 6B3, entrance 46, Corneel Heymanslaan 10, 9000 Gent
• LinkedIn 
• Radiobiology Lab
• Ellen Smekens is interested to receive invitations for presentations or talks